JW Holdings Corporation (096760.KS)
KRW 3045.0
(0.0%)
KRW 3045.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 446.15 Billion KRW | 7.94% |
| 2022 | 399.95 Billion KRW | 16.21% |
| 2021 | 344.17 Billion KRW | 12.01% |
| 2020 | 307.27 Billion KRW | 7.39% |
| 2019 | 286.13 Billion KRW | -7.67% |
| 2018 | 309.9 Billion KRW | 4.24% |
| 2017 | 297.3 Billion KRW | 7.23% |
| 2016 | 277.26 Billion KRW | 8.18% |
| 2015 | 256.3 Billion KRW | 8.76% |
| 2014 | 235.66 Billion KRW | 6.51% |
| 2013 | 221.25 Billion KRW | 10.98% |
| 2012 | 199.35 Billion KRW | -5.05% |
| 2011 | 209.95 Billion KRW | -12.6% |
| 2010 | 240.22 Billion KRW | -7.54% |
| 2009 | 259.8 Billion KRW | 3.19% |
| 2008 | 251.77 Billion KRW | 135.47% |
| 2007 | 106.92 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 95.96 Billion KRW | -10.88% |
| 2024 Q1 | 107.67 Billion KRW | -12.62% |
| 2023 Q1 | 103.72 Billion KRW | -13.57% |
| 2023 Q3 | 103.19 Billion KRW | -8.41% |
| 2023 FY | 431.71 Billion KRW | 7.94% |
| 2023 Q4 | 123.22 Billion KRW | 19.41% |
| 2023 Q2 | 112.67 Billion KRW | 8.63% |
| 2022 Q4 | 120 Billion KRW | 23.77% |
| 2022 Q2 | 91.18 Billion KRW | -0.68% |
| 2022 FY | 399.95 Billion KRW | 16.21% |
| 2022 Q1 | 91.8 Billion KRW | -7.9% |
| 2022 Q3 | 96.95 Billion KRW | 6.33% |
| 2021 Q4 | 99.68 Billion KRW | 36.7% |
| 2021 FY | 344.17 Billion KRW | 12.01% |
| 2021 Q1 | 86.69 Billion KRW | -1.25% |
| 2021 Q2 | 84.88 Billion KRW | -2.09% |
| 2021 Q3 | 72.91 Billion KRW | -14.1% |
| 2020 Q2 | 71.54 Billion KRW | -4.47% |
| 2020 Q1 | 74.88 Billion KRW | 37.44% |
| 2020 FY | 307.27 Billion KRW | 7.39% |
| 2020 Q4 | 87.79 Billion KRW | 20.18% |
| 2020 Q3 | 73.05 Billion KRW | 2.12% |
| 2019 Q4 | 54.48 Billion KRW | -30.16% |
| 2019 Q3 | 78.02 Billion KRW | -1.19% |
| 2019 Q2 | 78.96 Billion KRW | 5.78% |
| 2019 Q1 | 74.65 Billion KRW | 22.31% |
| 2019 FY | 286.13 Billion KRW | -7.67% |
| 2018 Q4 | 61.03 Billion KRW | -34.41% |
| 2018 Q1 | 77.7 Billion KRW | 14.23% |
| 2018 FY | 309.9 Billion KRW | 4.24% |
| 2018 Q2 | 78.1 Billion KRW | 0.51% |
| 2018 Q3 | 93.05 Billion KRW | 19.14% |
| 2017 Q3 | 70.26 Billion KRW | -11.74% |
| 2017 FY | 297.3 Billion KRW | 7.23% |
| 2017 Q4 | 68.02 Billion KRW | -3.18% |
| 2017 Q1 | 79.4 Billion KRW | 16.74% |
| 2017 Q2 | 79.61 Billion KRW | 0.26% |
| 2016 Q1 | 67.23 Billion KRW | 2.37% |
| 2016 Q2 | 71.92 Billion KRW | 6.97% |
| 2016 Q3 | 70.09 Billion KRW | -2.55% |
| 2016 FY | 277.26 Billion KRW | 8.18% |
| 2016 Q4 | 68.01 Billion KRW | -2.96% |
| 2015 FY | 256.3 Billion KRW | 8.76% |
| 2015 Q4 | 65.67 Billion KRW | 0.05% |
| 2015 Q2 | 65.87 Billion KRW | 12.55% |
| 2015 Q1 | 58.53 Billion KRW | -12.83% |
| 2015 Q3 | 65.64 Billion KRW | -0.35% |
| 2014 Q3 | 61.83 Billion KRW | 17.23% |
| 2014 Q2 | 52.74 Billion KRW | -1.29% |
| 2014 Q1 | 53.43 Billion KRW | -3.04% |
| 2014 FY | 235.66 Billion KRW | 6.51% |
| 2014 Q4 | 67.14 Billion KRW | 8.6% |
| 2013 Q1 | 56.25 Billion KRW | 7.95% |
| 2013 Q3 | 54.28 Billion KRW | -2.41% |
| 2013 Q4 | 55.1 Billion KRW | 1.52% |
| 2013 FY | 221.25 Billion KRW | 10.98% |
| 2013 Q2 | 55.62 Billion KRW | -1.13% |
| 2012 Q4 | 52.11 Billion KRW | -2.92% |
| 2012 Q2 | 51.92 Billion KRW | 28.28% |
| 2012 Q1 | 40.47 Billion KRW | 0.0% |
| 2012 FY | 199.35 Billion KRW | -5.05% |
| 2012 Q3 | 53.68 Billion KRW | 3.39% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 209.95 Billion KRW | -12.6% |
| 2011 Q2 | 11.63 Billion KRW | 209.68% |
| 2011 Q1 | 3.75 Billion KRW | 0.0% |
| 2011 Q3 | 10.6 Billion KRW | -8.88% |
| 2010 Q3 | 4.43 Billion KRW | -9.06% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | 240.22 Billion KRW | -7.54% |
| 2010 Q2 | 4.87 Billion KRW | 23.06% |
| 2010 Q1 | 3.96 Billion KRW | 0.0% |
| 2009 FY | 259.8 Billion KRW | 3.19% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 4.92 Billion KRW | 7.87% |
| 2009 Q2 | 4.56 Billion KRW | 16.16% |
| 2009 Q1 | 3.93 Billion KRW | 0.0% |
| 2008 FY | 251.77 Billion KRW | 135.47% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 2.98 Billion KRW | -4.09% |
| 2008 Q3 | 3.22 Billion KRW | 8.05% |
| 2008 Q1 | 3.1 Billion KRW | 0.0% |
| 2007 FY | 106.92 Billion KRW | 0.0% |
| 2007 Q3 | 2.52 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -859.373% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | -22.534% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -124.327% |
| HANDOK Inc. | 151.36 Billion KRW | -194.753% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -563.681% |
| Yuhan Corporation | 564.5 Billion KRW | 20.965% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | -38.467% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -1778.787% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 46.623% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -494.562% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -124.242% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -997.567% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -372.046% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -216.747% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -859.373% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -1185.17% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -480.795% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 3803.895% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -114.975% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 31.92% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -32.914% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -467.487% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -492.994% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -517.847% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -142.721% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -859.373% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | -51.179% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 34.538% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -32.914% |
| Yuhan Corporation | 564.5 Billion KRW | 20.965% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -121.065% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -528.93% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -350.54% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -32.914% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -205.814% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -157.169% |
| CKD Bio Corp. | 5.01 Billion KRW | -8804.789% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | -75.492% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -142.313% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -354.68% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -467.487% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | -20.097% |
| Boryung Corporation | 333.26 Billion KRW | -33.873% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -791.502% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -124.242% |
| JW Lifescience Corporation | 51.32 Billion KRW | -769.278% |